/PRNewswire/ The "Global Hand, Foot, and Mouth Disease Market, By Virus Type; By Drug Type; By Route of Administration; By Distribution Channel -Estimation.
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook - Continue to advance and expand opportunities with established. | April 3, 2022
Aeterna Zentaris Reports Second Quarter 2021 Financial globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
expected
beyond 2023
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2021. The Company also provided an update on its preclinical and clinical development programs.
“Over the course of the first quarter, we continued to execute on our key strategic priorities by significantly strengthening our balance sheet and expanding our development pipeline. This solid execution provides us with optionality to advance and accelerate our pipeline programs,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna.